Cytokeratin 17 (KRT17) (Basal Epithelial Marker) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone KRT17/778 ]
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| IHC, IF, FC |
---|---|
Primary Accession | Q04695 |
Other Accession | 3872, 2785 |
Reactivity | Human, Rat, Pig, Goat, Bovine |
Host | Mouse |
Clonality | Monoclonal |
Isotype | Mouse / IgG2b, kappa |
Clone Names | KRT17/778 |
Calculated MW | 46kDa |
Gene ID | 3872 |
---|---|
Other Names | Keratin, type I cytoskeletal 17, 39.1, Cytokeratin-17, CK-17, Keratin-17, K17, KRT17 |
Storage | Store at 2 to 8°C.Antibody is stable for 24 months. |
Precautions | Cytokeratin 17 (KRT17) (Basal Epithelial Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | KRT17 |
---|---|
Function | Type I keratin involved in the formation and maintenance of various skin appendages, specifically in determining shape and orientation of hair (By similarity). Required for the correct growth of hair follicles, in particular for the persistence of the anagen (growth) state (By similarity). Modulates the function of TNF-alpha in the specific context of hair cycling. Regulates protein synthesis and epithelial cell growth through binding to the adapter protein SFN and by stimulating Akt/mTOR pathway (By similarity). Involved in tissue repair. May be a marker of basal cell differentiation in complex epithelia and therefore indicative of a certain type of epithelial 'stem cells'. Acts as a promoter of epithelial proliferation by acting a regulator of immune response in skin: promotes Th1/Th17-dominated immune environment contributing to the development of basaloid skin tumors (By similarity). May act as an autoantigen in the immunopathogenesis of psoriasis, with certain peptide regions being a major target for autoreactive T-cells and hence causing their proliferation. |
Cellular Location | Cytoplasm {ECO:0000250|UniProtKB:Q9QWL7}. |
Tissue Location | Expressed in the outer root sheath and medulla region of hair follicle specifically from eyebrow and beard, digital pulp, nail matrix and nail bed epithelium, mucosal stratified squamous epithelia and in basal cells of oral epithelium, palmoplantar epidermis and sweat and mammary glands. Also expressed in myoepithelium of prostate, basal layer of urinary bladder, cambial cells of sebaceous gland and in exocervix (at protein level) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as �epithelial stem cell� marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.
References
(1) Smedts et. al. Am J Pathol 141: 497, 1992. (2) Smedts et. al. Am J Pathol 140: 601, 1992.(3) Wetzels et. al. Histopathol 20: 295, 1992. |
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.